We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$3.59M
2
HOLX
Hologic
HOLX
+$3.48M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.34M
4
AGN
Allergan plc
AGN
+$3.33M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVNS
51
DELISTED
Avanos Medical
AVNS
$2.78M 0.58%
+40,560
New +$2.61M
LLY icon
52
CALL
Eli Lilly
LLY
$1.08T
$2.68M 0.56%
+25,000
New +$2.5M
TFX icon
53
PUT
Teleflex
TFX
$5.91B
$2.66M 0.56%
+10,000
New +$2.59M
NVTR
54
DELISTED
Nuvectra Corporation Common Stock
NVTR
$2.52M 0.53%
114,616
+49,616
+76% +$955K
ZGNX
55
CALL
DELISTED
Zogenix, Inc.
ZGNX
$2.48M 0.52%
50,000
– –
XENT
56
DELISTED
Intersect ENT, Inc
XENT
$2.4M 0.51%
83,527
+11,027
+15% +$331K
ATRC icon
57
AtriCure
ATRC
$2.18B
$2.37M 0.5%
+67,670
New +$2.14M
MRTX
58
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.35M 0.5%
+50,000
New +$2.78M
RCM
59
DELISTED
R1 RCM Inc. Common Stock
RCM
$2.31M 0.49%
+227,109
New +$2.07M
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$2.22M 0.47%
44,718
-550
-1% -$28K
ALKS icon
61
CALL
Alkermes
ALKS
$8.26B
$2.12M 0.45%
+50,000
New +$2.17M
ALXN
62
DELISTED
Alexion Pharmaceuticals
ALXN
$2.1M 0.44%
15,124
+5,124
+51% +$643K
TSRO
63
DELISTED
TESARO, Inc.
TSRO
$1.98M 0.42%
+50,747
New +$1.79M
PBH icon
64
PUT
Prestige Consumer Healthcare
PBH
$2.54B
$1.9M 0.4%
+50,000
New +$1.89M
IMGN
65
CALL
DELISTED
Immunogen Inc
IMGN
$1.89M 0.4%
+200,000
New +$1.92M
VCRA
66
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$1.85M 0.39%
+50,622
New +$1.66M
VTRS icon
67
CALL
Viatris
VTRS
$18.7B
$1.83M 0.39%
50,000
-25,000
-33% -$938K
EXEL icon
68
CALL
Exelixis
EXEL
$12.7B
$1.77M 0.37%
+100,000
New +$1.95M
NTRA icon
69
Natera
NTRA
$45.1B
$1.7M 0.36%
+70,871
New +$1.71M
LAB icon
70
Standard BioTools
LAB
$309M
$1.69M 0.35%
+225,000
New +$1.6M
SPPI
71
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.68M 0.35%
100,000
– –
PACB icon
72
Pacific Biosciences
PACB
$354M
$1.64M 0.35%
+303,734
New +$1.3M
VRAY
73
CALL
DELISTED
ViewRay, Inc.
VRAY
$1.64M 0.34%
175,000
-25,000
-13% -$246K
AXDX
74
CALL
DELISTED
Accelerate Diagnostics
AXDX
$1.61M 0.34%
7,000
– –
QGEN icon
75
CALL
Qiagen
QGEN
$8.81B
$1.51M 0.32%
37,722
-56,584
-60% -$2.26M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.